Premium
miR‐216a may inhibit pancreatic tumor growth by targeting JAK2
Author(s) -
Hou Bao-hua,
Jian Zhi-xiang,
Cui Peng,
Li Shao-jie,
Tian Rui-qing,
Ou Jin-rui
Publication year - 2015
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2015.06.036
Subject(s) - pancreatic cancer , cancer research , in vivo , ca19 9 , medicine , suppressor , cancer , endocrinology , biology , microbiology and biotechnology
This study was aimed to investigate miR‐216a expression in pancreatic cancer and determine its effects on proliferation. miR‐216a was found downregulated in pancreatic cancer tissues as compared to benign pancreatic lesions. JAK2 was identified as a miR‐216a gene target. Further, in vivo treatment of PANC‐1 tumors with miR‐216a reduced JAK2 protein levels in the tumor and reduced tumor volume. In conclusion, miR‐216a may function as a tumor suppressor regulating pancreatic cancer cells by targeting the JAK/STAT pathway. Further studies with a larger number of patient samples are necessary to fully explore the diagnostic and therapeutic potential of miR‐216a for pancreatic cancer.